Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2019 Annual Meeting

NEW YORK--(BUSINESS WIRE)-- Flatiron Health today announced 16 abstracts accepted for presentation at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 - June 4 in Chicago. The research, spanning multiple tumor types and areas of study, utilized Flatiron’s high-quality, real-world oncology datasets.

The research to be presented includes collaborations between Flatiron and the U.S. Food and Drug Administration, National Cancer Institute, Amgen, Eli Lilly and Company, Pfizer, Roche/Genentech and Foundation Medicine.

The presentation schedule and links to abstracts can be found below. Learn more about our abstracts by clicking on each link or see our recent blog post for more information.

Plenary Session

Affordable Care Act (ACA) Medicaid Expansion Impact on Racial Disparities in Time to Cancer Treatment

• Presenting Author: Amy Davidoff, PhD (Yale School of Public Health)
• Date/Time: June 2 — 1:45 - 2:00pm
• Abstract: #LBA1
• Location: Hall B1
• Track: Special Sessions

Poster Discussion

Genomic Characterization of Lung Tumors and Metastatic Sites in Advanced NSCLC

• First Author: Melinda Willard (Eli Lilly and Company)
• Date/Time: June 2 — 4:30 - 6:00pm
• Abstract: #2014
• Poster: #203
• Location: S404
• Track: Central Nervous System Tumors

Poster Sessions (Location: Hall A)

Organ Dysfunction and Clinical Outcomes in Patients Treated with Immune Checkpoint Inhibitors

• First Author: Qi Li, PhD (U.S. Food and Drug Administration)
• Date/Time: June 1 — 8:00 - 11:00am
• Abstract: #2569
• Poster: #213
• Track: Developmental Immunotherapy and Tumor Immunobiology

Tumor Mutational Burden and PD-L1 Expression as Predictors of Response to Immunotherapy in NSCLC

• First Author: Emily Castellanos, MD, MPH (Flatiron Health)
• Date/Time: June 1 — 8:00 - 11:00am
• Abstract: #2630
• Poster: #274
• Track: Developmental Immunotherapy and Tumor Immunobiology

Impact of Oncology Care Model Reporting Requirements on Quality of Care

• First Author: Emily Castellanos, MD, MPH (Flatiron Health)
• Date/Time: June 1 — 1:15 - 4:15pm
• Abstract: #6620
• Poster: #311
• Track: Health Services Research, Clinical Informatics, and Quality of Care

Using Real-World Cohorts to Assess the Generalizability and Relevance of Randomized Clinical Trials

• First Author: Caroline Bennette, MPH, PhD (Flatiron Health)
• Date/Time: June 1 — 1:15 - 4:15pm
• Abstract: #6540
• Poster: #231
• Track: Health Services Research, Clinical Informatics, and Quality of Care

Clinical Characteristics, Treatment Patterns, and Overall Survival in Advanced NSCLC Patients With and Without Brain Metastases

• First Author: Emily Nash Smyth, PharmD (Eli Lilly and Company)
• Date/Time: June 2 — 8:00 - 11:00am
• Abstract: #2035
• Poster: #224
• Track: Central Nervous System Tumors

Identification and Use of Treatment Options in Patients with Advanced Non-Small Cell Lung Cancer After Comprehensive Genomic Profiling: A Real-World Study

• First Author: Celine Mascaux, MD, PhD (Aix-Marseille University)
• Date/Time: June 2 — 8:00 - 11:00am
• Abstract: #9076
• Poster: #399
• Track: Lung Cancer—Non-Small Cell Metastatic

Real-World Evidence of Male Breast Cancer Patients Treated with Palbociclib in Combination with Endocrine Therapy

• First Author: Cynthia Huang Bartlett, MD (Pfizer)
• Date/Time: June 2 — 8:00 - 11:00am
• Abstract: #1055
• Poster: #136
• Track: Breast Cancer—Metastatic

Real-World Practice Patterns and Impact of PD-L1 Expression Testing in Patients with Advanced Non-Small Cell Lung Cancer

• First Author: Michael Leapman, MD (Yale School of Medicine)
• Date/Time: June 2 — 8:00 - 11:00am
• Abstract: #9059
• Poster: #382
• Track: Lung Cancer—Non-Small Cell Metastatic

Real-World Utilization of EGFR TKI Therapies and Treatment Outcomes in Patients with Advanced EGFR-Sensitizing Mutation-Positive NSCLC

• First Author: Gregory J. Riely, MD, PhD (Memorial Sloan Kettering Cancer Center)
• Memorial Sloan Kettering Cancer Center
• Date/Time: June 2 — 8:00 - 11:00am
• Abstract: #9062
• Poster: #385
• Track: Lung Cancer—Non-Small Cell Metastatic

Time-to-Treatment Discontinuation and Real-World Progression-Free Survival as Endpoints for Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive NSCLC Patients

• First Author: Robert Charles Doebele, MD, PhD (University of Colorado)
• Date/Time: June 2 — 8:00 - 11:00am
• Abstract: #9070
• Poster: #393
• Track: Lung Cancer—Non-Small Cell Metastatic

Validation of Broad Panel Clinical Sequencing-Based Genomic Risk Stratification in Patients with Advanced Lung Adenocarcinomas

• First Author: Sam Whipple, MSPH (Genentech)
• Date/Time: June 2 — 8:00 - 11:00am
• Abstract #9113
• Poster #436
• Track: Lung Cancer—Non-Small Cell Metastatic

Chromosome 1 Abnormalities and Clinical Outcomes in Multiple Myeloma in the Era of Novel Agents

• First Author: Smith Giri, MBBS (Yale School of Medicine)
• Date/Time: June 3 — 8:00 - 11:00am
• Abstract: #8044
• Poster: #370
• Track: Hematologic Malignancies—Plasma Cell Dyscrasia

Burden of Thrombocytopenia in Adult Cancer Patients Receiving Chemotherapy

• First Author: Gerald Soff, MD (Memorial Sloan Kettering Cancer Center)
• Date/Time: June 3 — 1:15 - 4:15pm
• Abstract: #1555
• Poster: #49
• Track: Cancer Prevention, Hereditary Genetics, and Epidemiology

Treatment Characteristics of Patients with Locally Advanced or Metastatic Urothelial Cancer (mUC) Receiving Checkpoint Inhibitor Monotherapy in a US Clinical Practice

• First Author: Alicia Morgans, MD, MPH (Northwestern University)
• Date/Time: June 3 — 1:15 - 4:15pm
• Abstract: #4526
• Poster: #352
• Track: Genitourinary (Nonprostate) Cancer

About Flatiron Health

Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. Our platform enables cancer researchers and care providers to learn from the experience of every patient. Currently, Flatiron partners with over 280 community cancer practices, seven major academic research centers and over 15 of the top therapeutic oncology companies. For more information, please visit http://flatiron.com or follow us @FlatironHealth.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005661/en/